Evidence map›Paper›PMID 41675328›Full record

ReviewTranslational gastroenterology and hepatology2026

The role of hepcidin in the inflammatory and iron homeostasis axis in inflammatory bowel diseases: a systematic review.

Livia Fontana Parreira, Adherbal Víctor Rodrigues Teixeira, Sofia Souza Nunes Siqueira, Natalia Souza Nunes Siqueira, Marina Moreira de Castro, Lívia Moreira Genaro, Isabela Machado Pereira, Nicole Compagnoni Gallina, Raquel Franco Leal

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Livia Fontana ParreiraInflammatory Bowel Disease Research Laboratory (LABDII), Gastrocenter, Colorectal Surgery Unit, Surgery Department, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Adherbal Víctor Rodrigues TeixeiraInflammatory Bowel Disease Research Laboratory (LABDII), Gastrocenter, Colorectal Surgery Unit, Surgery Department, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Sofia Souza Nunes SiqueiraInflammatory Bowel Disease Research Laboratory (LABDII), Gastrocenter, Colorectal Surgery Unit, Surgery Department, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Natalia Souza Nunes SiqueiraInflammatory Bowel Disease Research Laboratory (LABDII), Gastrocenter, Colorectal Surgery Unit, Surgery Department, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Marina Moreira de CastroInflammatory Bowel Disease Research Laboratory (LABDII), Gastrocenter, Colorectal Surgery Unit, Surgery Department, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Lívia Moreira GenaroInflammatory Bowel Disease Research Laboratory (LABDII), Gastrocenter, Colorectal Surgery Unit, Surgery Department, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Isabela Machado PereiraInflammatory Bowel Disease Research Laboratory (LABDII), Gastrocenter, Colorectal Surgery Unit, Surgery Department, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Nicole Compagnoni GallinaInflammatory Bowel Disease Research Laboratory (LABDII), Gastrocenter, Colorectal Surgery Unit, Surgery Department, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.
Raquel Franco LealInflammatory Bowel Disease Research Laboratory (LABDII), Gastrocenter, Colorectal Surgery Unit, Surgery Department, School of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Inflammatory bowel disease (IBD), which encompasses Crohn's disease (CD) and ulcerative colitis (UC), is characterized by chronic inflammation of the gastrointestinal tract. Anemia is a common complication in patients with IBD, significantly impacting quality of life. Hepcidin, the primary regulator of iron metabolism, exhibits increased expression during inflammatory states, contributing to the development of anemia of inflammation. Understanding the relationship between hepcidin and IBD is essential to improving the diagnosis and management of this complication. This article aimed to systematically review and synthesize the evidence on the associative and predictive utility of hepcidin as a biomarker for inflammatory activity, iron status, and anemia management in patients with IBD. Methods: A systematic review (SR) (PROSPERO identification number: CRD42024375586) was conducted across the databases PubMed, PubMed PMC, BVS/BIREME, Scopus, Web of Science, Embase, EBSCOhost, and ProQuest, including studies published up to July 2024. The research question was structured using the PICO strategy (Patient/Problem, Intervention, Comparison, and Outcome) to guide study selection and analysis. Original articles investigating hepcidin expression in patients with IBD and its association with inflammatory markers and iron status were included. Study selection, data extraction, and methodological quality assessment were performed independently by three reviewers using the Rayyan platform. Results: Of the 342 studies identified, 47 met the inclusion criteria for qualitative analysis. The majority of studies reported elevated hepcidin levels in patients with active IBD compared to healthy controls or patients in remission. Hepcidin expression was positively correlated with inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6), and negatively correlated with serum iron parameters and hemoglobin levels. Conclusions: Hepcidin plays a central role in the pathophysiology of anemia associated with IBD, reflecting systemic inflammatory status. Its quantification may represent a valuable tool for the differential diagnosis of anemia and for guiding targeted therapies. Further longitudinal studies are required to validate its routine clinical use.

Indexed as

anemia of inflammationhepcidinInflammatory bowel disease (IBD)ironsystematic review

Identifiers

PMID41675328
PMCPMC12887308

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.